What it's for (Indications)
- Cefpirome is a broad-spectrum, fourth-generation cephalosporin antibiotic indicated for the treatment of serious bacterial infections caused by susceptible microorganisms.
- Its potent activity against a wide array of Gram-positive and Gram-negative pathogens, including *Pseudomonas aeruginosa* and some Enterobacteriaceae resistant to earlier-generation cephalosporins, makes it suitable for complicated infections.
- Specific indications include severe lower respiratory tract infections (e.
- g.
- , severe pneumonia), complicated urinary tract infections, severe skin and soft tissue infections, bacteremia, septicemia, and infections in neutropenic patients.
- The decision to use cefpirome should be based on susceptibility testing and local epidemiological data, considering its efficacy against multi-drug resistant pathogens where appropriate.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefpirome (e.g., Iprome) must be carefully individualized based on the severity and type of infection, the patient's renal function, and age. For adults with normal renal function (creatinine clearance > 60 mL/min), typical intravenous dosages range from 1 gram to 2 grams administered every 12 hours. In cases of very severe or life-threatening infections, dosages up to 2 grams every 8 hours may be considered, not exceeding 6 grams per day. Crucially, significant dosage adjustment is required for patients with impaired renal function, with reduced doses or extended dosing intervals to prevent drug accumulation and potential toxicity. Pediatric dosing is also weight-based and specific to age groups and should always follow established guidelines. The duration of therapy depends on the clinical response, the specific pathogen, and the eradication of the infection. |
Safety & Warnings
Common Side Effects
- Cefpirome, like other broad-spectrum antibiotics, can cause a range of side effects, which are generally mild and transient but can occasionally be severe.
- Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort.
- Local reactions at the injection site, including pain, inflammation, or phlebitis, are also frequently reported.
- Less common but more serious side effects encompass hypersensitivity reactions, which can manifest as skin rash, pruritus, urticaria, angioedema, and, rarely, severe anaphylaxis.
- Hematological abnormalities, such as eosinophilia, thrombocytopenia, leukopenia, and a positive Coombs test, have been observed.
- Renal dysfunction, elevated liver enzymes, and neurological disturbances, including dizziness, headaches, and particularly seizures (especially in patients with renal impairment), are also potential concerns.
- *Clostridioides difficile*-associated diarrhea (CDAD) is a significant risk that must be considered in any patient presenting with new-onset diarrhea during or after antibiotic use.
Serious Warnings
- Black Box Warning: **(Note: Cefpirome does not carry a formal FDA Black Box Warning. The following details serious warnings as per guideline requirements.)** **Serious Warnings:** **1. Severe Hypersensitivity Reactions:** Life-threatening hypersensitivity reactions, including anaphylaxis, can occur with cefpirome and other cephalosporins. Patients with a history of penicillin allergy or severe allergic reactions to other beta-lactam antibiotics are at an increased risk. Careful inquiry about previous allergic reactions, particularly those that were severe or immediate, is crucial before initiating therapy. If a severe allergic reaction occurs, cefpirome must be immediately discontinued, and appropriate emergency medical treatment (e.g., epinephrine, corticosteroids, airway management) must be administered without delay. These reactions can be fatal if not promptly managed. **2. *Clostridioides difficile*-associated Diarrhea (CDAD):** *Clostridioides difficile* infection (CDI) and associated diarrhea (CDAD) have been reported with nearly all antibacterial agents, including cefpirome. CDAD severity can range from mild diarrhea to fatal colitis. It is essential to consider CDAD in all patients presenting with diarrhea following antibiotic use. Diagnosis requires careful clinical evaluation and laboratory confirmation of *C. difficile* toxins or gene. If CDAD is suspected or confirmed, cefpirome should be discontinued, and appropriate treatment for *C. difficile* infection should be initiated, along with supportive care. Delayed diagnosis and treatment can lead to severe complications, including toxic megacolon and perforation. **3. Neurotoxicity, particularly in Renal Impairment:** High concentrations of cefpirome, especially in patients with impaired renal function where drug accumulation can occur due to its primary renal clearance, may lead to severe neurological disturbances. These can manifest as encephalopathy, myoclonus, confusion, stupor, and seizures. Since cefpirome is primarily renally cleared, careful monitoring of renal function (e.g., creatinine clearance) and appropriate dosage adjustments based on the degree of renal impairment are absolutely essential to mitigate the risk of these serious central nervous system adverse events. Patients with pre-existing neurological disorders or compromised renal function are particularly vulnerable. Discontinuation of cefpirome may be necessary if neurological symptoms develop, and symptomatic treatment should be provided.
- Patients receiving cefpirome should be closely monitored for several critical warnings.
- A primary concern is the potential for severe hypersensitivity reactions, including anaphylaxis, which can be life-threatening.
- A thorough history of allergies, especially to penicillins or other beta-lactam antibiotics, is paramount before initiating treatment due to potential cross-reactivity.
- If an allergic reaction occurs, the drug must be discontinued immediately.
- The development of *Clostridioides difficile*-associated diarrhea (CDAD) is a serious complication that can range from mild to severe and potentially fatal; it should be considered in any patient presenting with diarrhea post-antibiotic use.
- Renal function must be carefully assessed and monitored throughout therapy, especially in elderly patients or those with pre-existing renal impairment, as dose adjustments are essential to prevent accumulation and potential neurotoxicity, including seizures and encephalopathy.
- Prolonged use may lead to superinfection with resistant bacteria or fungi.
- Coagulation disorders, though rare, have been reported with some cephalosporins and warrant monitoring.
How it Works (Mechanism of Action)
Cefpirome exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. As a beta-lactam antibiotic, its primary mechanism involves binding to and inactivating penicillin-binding proteins (PBPs) located on the inner bacterial cell membrane. These PBPs are crucial enzymes involved in the transpeptidation step of peptidoglycan synthesis, which is vital for maintaining the structural integrity and rigidity of the bacterial cell wall. By disrupting this process, cefpirome leads to a defective cell wall, resulting in osmotic instability, bacterial lysis, and ultimately cell death. As a fourth-generation cephalosporin, cefpirome possesses an enhanced spectrum of activity, demonstrating excellent stability against hydrolysis by a broader range of beta-lactamases produced by both Gram-positive and Gram-negative bacteria, including those often resistant to earlier generation cephalosporins. This stability contributes to its efficacy against resistant strains, including *Pseudomonas aeruginosa*.